Analysts at UBS AG (NYSE: UBS) initiated coverage on shares of PSS World Medical (NASDAQ: PSSI) in a research report issued to clients and investors on Monday. The firm set a “buy” rating and a $26.00 price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at Robert W. Baird downgraded shares of PSS World Medical from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, May 11st. They now have a $21.00 price target on the stock, down previously from $29.00. Analysts at Raymond James (NYSE: RJF) downgraded shares of PSS World Medical from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, May 10th.
Shares of PSS World Medical traded down 0.54% during mid-day trading on Monday, hitting $19.225. PSS World Medical has a one year low of $18.51 and a one year high of $29.47. The company has a market cap of $965.2 million and a P/E ratio of 14.01.
PSS World Medical last issued its quarterly earnings data on Thursday, May 10th. The company reported $0.38 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.43 by $0.05. The company’s quarterly revenue was down 2.0% on a year-over-year basis. On average, analysts predict that PSS World Medical will post $0.36 earnings per share next quarter.
PSS World Medical, Inc. (PSSI) is a distributor of medical products and equipment, pharmaceutical products, healthcare information technology and billing services to alternate-site healthcare providers, including physician offices, long-term care and assisted living facilities, home healthcare and hospice providers.